UK markets close in 2 hours 36 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
46.61-1.08 (-2.26%)
At close: 04:00PM EDT
48.40 +1.79 (+3.84%)
Pre-market: 08:48AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close47.69
Open47.56
Bid39.94 x 100
Ask46.72 x 200
Day's range46.31 - 47.57
52-week range42.63 - 56.26
Volume1,662,059
Avg. volume1,929,487
Market cap118.154B
Beta (5Y monthly)0.45
PE ratio (TTM)20.35
EPS (TTM)2.29
Earnings dateN/A
Forward dividend & yield2.04 (4.37%)
Ex-dividend date09 May 2024
1y target est59.12
  • Investor's Business Daily

    AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags

    AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

  • Reuters

    UPDATE 2-Sanofi profit slips on generic competition and currency effects

    Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.

  • Reuters

    Sanofi profit slips on generic competition and currency effects

    (Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.